A Study of Optical Imaging With Light From Radiotracers in Cancer Patients

Thyroid Cancer Clinical Trial

Official title:

A Feasibility Study of Non-Invasive Cerenkov Luminescence Imaging in Patients With Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03484884
• Other study ID #: 17-538
• Status: Active, not recruiting
• Start date: March 20, 2018
• Est. completion date: March 2025

Study information

• Verified date: December 2023
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to test Cerenkov luminescence imaging, which is a different way to take pictures of thyroid cancer and/or any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 102
• Est. completion date: March 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participant is 18 years of age or old

• Participant must meet one of the following:

• Patients with thyroid cancer scheduled for thyroid ablation therapy with 131I

• Patients with any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region who are scheduled to receive a clinical FDG PET/CT scan

• Patients with metastatic prostate cancer who are schedule for Xofigo therapy with 223Ra

• Patients scheduled to receive a standard of care 66Ga-DOTA-TATE or [18f]-PARPi PET scan in the Nuclear Medicine Clinic

• Patient undergoing Lu-DOTA TATE treatment in the Nuclear Medicine Clinic

Exclusion Criteria:

• Patients imaged for Cerenkov luminescence are going to be required to be in a darkened enclosure for at least 10 minutes and sit still during image acquisition. Any conditions that would prevent this will exclude the patients. This includes patients who unable to sit in a dark environment, have claustrophobic, inability to sit still for a few minutes

• Any other past medical, physiological or demographic concerns. This includes any patients with skin blemishes that are present at the dermis over the tumor, as these are of particular interest for use of this technique. This also includes open wounds on the area of interest.

Related Conditions & MeSH terms

• Thyroid Cancer
• Thyroid Neoplasms

Intervention

Diagnostic Test:
• Cerenkov luminescence imaging.
Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.

Locations

Country	Name	City	State
United States	Memorial Sloan - Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of clinical Cerenkov luminescence imaging by achieving satisfactory imaging at least a rate of 80%	The primary objective is to explore the overall feasibility of clinical Cerenkov imaging on patients with any tumors with nodal metastases (existing or suspected) scheduled for routine clinical FDG PET or 131I therapy.	Through study completion, an average of 24 hours

External Links

•   Memorial Sloan Kettering Cancer Center